Takeda Pharmaceutical Co Ltd v. Annora Pharma Pvt Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Takeda Pharmaceutical Company Limited (Japan)
  • Defendant: Annora Pharma Private Limited (India)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-01780, D.N.J., 02/23/2026
• Venue Allegations: Venue is based on allegations that Defendant Annora conducts business in New Jersey, will market its generic product in the district, and has previously consented to jurisdiction and venue in the district in prior patent litigation.
• Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) to market a generic version of LIVTENCITY® (maribavir) infringes six U.S. patents related to maribavir compositions, methods of use, and synthesis.
• Technical Context: The technology relates to antiviral therapies for treating cytomegalovirus (CMV), a common and significant viral complication for post-transplant patients.
• Key Procedural History: This action was filed under 35 U.S.C. § 271(e)(2) in response to a Paragraph IV certification submitted by Annora as part of its ANDA No. 221113. The complaint certifies that a related matter is pending, involving the same plaintiff and patents against a different defendant.

Case Timeline

Date	Event
2010-10-28	Priority Date for '632 and '169 Patents
2021-11-19	Priority Date for '989, '907, and '170 Patents
2022-10-12	Priority Date for '940 Patent
2023-06-27	'632 Patent Issued
2025-02-04	'989 Patent Issued
2025-05-13	'940 Patent Issued
2025-10-07	'907 Patent Issued
2025-10-21	'169 Patent Issued
2025-10-21	'170 Patent Issued
2026-01-12	Annora's Notice Letter to Takeda
2026-02-23	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,684,632, Maribavir Isomers, Compositions, Methods of Making and Methods of Using, issued June 27, 2023

The Invention Explained

• Problem Addressed: The patent discloses that the antiviral compound maribavir can convert in vivo into various isomers-molecules with the same chemical formula but a different structure-that may possess lower biological activity '632 Patent, col. 1:56-2:9 This isomerization is believed to have contributed to the failure of a Phase 3 clinical trial, as it effectively dilutes the concentration of the active drug in the body, particularly when dosed with food '632 Patent, col. 2:19-54
• The Patented Solution: To counteract this effect, the invention claims specific methods of administering maribavir to enhance its efficacy and bioavailability. A central aspect of the solution is administering the drug under "fasted conditions," which are defined as not consuming food for a specified period before and after taking the drug '632 Patent, col. 5:55-64 The patent also claims specific dosing protocols for transplant recipients '632 Patent, claims 1 '632 Patent, claim 6 '632 Patent, claim 11
• Technical Importance: The invention provides a pharmacological explanation and potential solution for a failed clinical trial, aiming to salvage a promising drug by optimizing its dosing regimen to account for a previously unrecognized chemical instability in vivo '632 Patent, col. 2:40-54

Key Claims at a Glance

• The complaint alleges infringement of "one or more claims" of the '632 patent without specifying them Compl. ¶33 Independent claim 1 is representative of the method of use claims.
• The essential elements of independent claim 1 are:
  • A method for treatment of a herpes viral infection in a patient in need thereof comprising orally administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound,
  • in an amount of 400 mg twice a day,
  • wherein said patient is a stem cell transplant recipient. '632 Patent, col. 7:51-57
• The complaint's general allegation of infringing "one or more claims" may be interpreted as reserving the right to assert dependent claims Compl. ¶33

U.S. Patent No. 12,213,989, Use of Maribavir in Treatment Regimens, issued February 4, 2025

The Invention Explained

• Problem Addressed: Transplant patients often take multiple medications, creating a risk of drug-drug interactions (DDIs). Maribavir is metabolized primarily by the enzyme CYP3A4, and its exposure can be significantly altered when co-administered with drugs that induce CYP3A4 activity '989 Patent, col. 5:5-13 Such interactions can reduce maribavir's plasma concentration and potentially lead to a reduced virologic response '989 Patent, col. 6:9-13
• The Patented Solution: The patent discloses specific treatment regimens to manage these DDIs. It claims methods of treating CMV infection that involve co-administering maribavir with specific CYP3A4 inducers (e.g., phenytoin, phenobarbital) but at an increased maribavir dose, such as 1200 mg twice daily, to compensate for the reduced exposure '989 Patent, col. 2:9-19 '989 Patent, col. 7:1-8 The claims also cover regimens for co-administration with immunosuppressants '989 Patent, col. 7:59-8:10
• Technical Importance: The invention provides a clinically applicable framework for managing DDIs with maribavir, enabling its safe and effective use in complex, polymedicated transplant patients by proactively adjusting dosage based on known metabolic pathways '989 Patent, col. 1:24-30

Key Claims at a Glance

• The complaint alleges infringement of "one or more claims" of the '989 patent without specifying them Compl. ¶42 Independent claim 1 is a representative method claim.
• The essential elements of independent claim 1 are:
  • A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom, the method comprising administering maribavir in an amount of 1200 mg orally twice daily,
  • wherein the patient is a transplant recipient concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital,
  • wherein maribavir is administered prior to, concurrently with, or subsequently from the administration of the anticonvulsant. '989 Patent, col. 47:8-19
• The complaint's general allegation may be interpreted as reserving the right to assert additional claims Compl. ¶42

Multi-Patent Capsule: U.S. Patent No. 12,295,940

• Patent Identification: U.S. Patent No. 12,295,940, Viral Inhibitors, the Synthesis Thereof, and Intermediates Thereto, issued May 13, 2025 Compl. ¶6
• Technology Synopsis: The patent addresses the problem of inefficient and low-yield chemical syntheses for maribavir '940 Patent, col. 2:54-59 It discloses an improved, multi-step synthesis process designed to increase the overall yield and control impurities, making large-scale manufacturing more viable '940 Patent, col. 7:15-21
• Asserted Claims: The complaint generally alleges infringement of "one or more claims" Compl. ¶51
• Accused Features: The accused feature is Annora's ANDA Product, which is alleged to be made by a process that infringes the '940 patent's claims to methods of synthesis or compositions resulting from that synthesis Compl. ¶53

Multi-Patent Capsule: U.S. Patent No. 12,433,907

• Patent Identification: U.S. Patent No. 12,433,907, Use of Maribavir in Treatment Regimens, issued October 7, 2025 Compl. ¶7
• Technology Synopsis: This patent, related to the '989 patent, addresses drug-drug interactions between maribavir and co-administered drugs like anticonvulsants and immunosuppressants in transplant patients '907 Patent, col. 1:21-30 The invention claims specific methods for treating CMV that involve administering an adjusted dose of maribavir (e.g., 1200 mg twice daily) when a patient is also receiving a CYP3A4-inducing anticonvulsant, and also requires monitoring of the co-administered drug levels '907 Patent, claims 1 '907 Patent, claim 17
• Asserted Claims: The complaint generally alleges infringement of "one or more claims" Compl. ¶60
• Accused Features: The infringement allegation centers on the future use of Annora's ANDA Product according to its label, which Takeda alleges will instruct infringing methods of administration Compl. ¶13 Compl. ¶62 Compl. ¶63

Multi-Patent Capsule: U.S. Patent No. 12,447,169

• Patent Identification: U.S. Patent No. 12,447,169, Maribavir Isomers, Compositions, Methods of Making and Methods of Using, issued October 21, 2025 Compl. ¶8
• Technology Synopsis: This patent, related to the '632 patent, addresses the problem of maribavir's in vivo isomerization, which can decrease the drug's efficacy '169 Patent, col. 1:55-2:18 It claims methods of use that mitigate this effect, primarily by administering maribavir under "fasted conditions" to improve bioavailability and ensure therapeutic effectiveness '169 Patent, claim 3
• Asserted Claims: The complaint generally alleges infringement of "one or more claims" Compl. ¶69
• Accused Features: The infringement allegation is based on the intended use of Annora's ANDA Product, which Takeda alleges will follow the instructions on the branded drug's label, thereby infringing the patented methods Compl. ¶13 Compl. ¶71 Compl. ¶72

Multi-Patent Capsule: U.S. Patent No. 12,447,170

• Patent Identification: U.S. Patent No. 12,447,170, Use of Maribavir in Treatment Regimens, issued October 21, 2025 Compl. ¶9
• Technology Synopsis: This patent, related to the '989 patent, addresses drug-drug interactions involving maribavir in transplant recipients '170 Patent, col. 1:21-30 It claims methods for treating CMV infection by co-administering maribavir with specific anticonvulsants (e.g., carbamazepine) or immunosuppressants (e.g., tacrolimus), specifying dose adjustments for maribavir and requiring monitoring of the patient's drug levels '170 Patent, claims 1 '170 Patent, claim 11 '170 Patent, claim 17
• Asserted Claims: The complaint generally alleges infringement of "one or more claims" Compl. ¶78
• Accused Features: The infringement allegation is based on the intended use of Annora's ANDA Product according to its label, which Takeda alleges will instruct infringing methods of administration Compl. ¶13 Compl. ¶80 Compl. ¶81

III. The Accused Instrumentality

• Product Identification: Annora's ANDA Product, a generic version of LIVTENCITY®, which contains 200 mg of the active ingredient maribavir in tablet form for oral administration Compl. ¶27 Compl. ¶31
• Functionality and Market Context: The accused product is an antiviral drug, specifically a cytomegalovirus (CMV) pUL97 kinase inhibitor Compl. ¶10 It is indicated for treating adult and pediatric post-transplant patients with CMV infection or disease that is refractory to other existing antiviral treatments Compl. ¶10 The complaint alleges that Annora's submission of ANDA No. 221113 and its Paragraph IV certification represent a direct challenge to Takeda's patent estate covering LIVTENCITY® Compl. ¶2 Compl. ¶29 It further alleges that the FDA-approved label for LIVTENCITY® instructs and encourages administration according to methods claimed in the patents-in-suit Compl. ¶13 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

11,684,632 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for treatment of a herpes viral infection in a patient in need thereof	Annora's ANDA product is indicated for the treatment of CMV, which is a herpes virus, in post-transplant patients.	¶10	col. 2:31-39
comprising orally administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound,	Annora's ANDA Product is an oral tablet formulation of maribavir, the chemical name for the claimed compound.	¶27	col. 1:47-51
in an amount of 400 mg twice a day,	The FDA-approved label for LIVTENCITY®, which Annora's ANDA product label will copy, instructs a 400 mg twice-daily dosage.	¶13	col. 7:55-57
wherein said patient is a stem cell transplant recipient.	The ANDA product is indicated for post-transplant patients, a population that includes stem cell transplant recipients.	¶10	col. 2:20-23

• Identified Points of Contention:
  • Scope Questions: Claim 1 is directed to stem cell transplant recipients. A potential issue could be whether Annora's label specifically carves out this patient population. However, given the broad "post-transplant" indication Compl. ¶10, this seems unlikely.
  • Technical Questions: A key theme of the '632 patent is the importance of "fasted conditions" to mitigate isomerization (e.g., claim 3). While claim 1 does not include this limitation, a central dispute may revolve around whether administration under fasted conditions is an inherent or inevitable part of the product's intended use, which could be used to argue infringement of other, dependent claims.

12,213,989 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom, the method comprising administering maribavir in an amount of 1200 mg orally twice daily,	The FDA-approved label for LIVTENCITY® allegedly instructs a dose increase to 1200 mg twice daily when co-administered with certain drugs.	¶13	col. 7:7-13
wherein the patient is a transplant recipient	The accused product is indicated for use in post-transplant patients.	¶10	col. 1:24-26
concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital,	The LIVTENCITY® label contains information on co-administration with CYP3A4 inducers like phenytoin and phenobarbital, which is alleged to induce infringement.	¶13	col. 7:10-13
wherein maribavir is administered prior to, concurrently with, or subsequently from the administration of the anticonvulsant.	The instruction for co-administration implies a concurrent or overlapping treatment period.	¶13	col. 1:24-30

• Identified Points of Contention:
  • Scope Questions: The infringement allegation hinges on a specific clinical scenario-co-administration with strong CYP3A4 inducers. An open question for the court will be whether the language in Annora's proposed label rises to the level of actively inducing infringement, as opposed to merely providing cautionary information about a potential drug-drug interaction.
  • Technical Questions: The case may raise the evidentiary question of how frequently this specific DDI scenario occurs in the target patient population. Takeda may argue that co-prescription is common and foreseeable, while Annora may suggest it is a rare event for which it should not be held liable for infringement.

V. Key Claim Terms for Construction

'632 Patent

• The Term: "fasted conditions" (from claim 3)
• Context and Importance: The definition of this term is central to a key infringement theory of the '632 patent family. A broad definition would make infringement easier to prove from routine clinical use, while a narrow one would require Takeda to show that a very specific, prescribed fasting regimen is followed. Practitioners may focus on this term because it appears to be the patentee's primary solution to the technical problem of in vivo isomerization.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent provides a general definition: "the condition of not having consumed food during the period between from at least about 3 to 12 hours prior to the administration of maribavir to at least about 1 to 3 hours after the administration" '632 Patent, col. 5:55-64
  • Evidence for a Narrower Interpretation: The specification also states, "Other narrower 'fasted conditions' are also contemplated herein" ('632 Patent, col. 5:64-65) and provides a table with specific fasting protocols like "12 hrs/3 hrs" and "6 hrs/2 hrs" '632 Patent, col. 5-6, table A party may argue the term should be limited to these more specific, disclosed examples.

'989 Patent

• The Term: "increasing the amount of maribavir" (from claim 7)
• Context and Importance: This term is critical for claims directed at dose adjustments in response to DDIs. Its construction will determine what constitutes a legally cognizable act of "increasing" the dose. Practitioners may focus on this term because it defines the infringing act in the context of managing DDIs.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification provides context that the standard dose is 400 mg twice daily and that an "increase" is to "about 800 mg or about 1200 mg orally, twice daily" when co-administered with a CYP3A4 inducer '989 Patent, col. 6:45-53 This suggests "increasing" refers to a deliberate switch from a standard dose to a higher, specified dose based on a DDI.
  • Evidence for a Narrower Interpretation: The patent does not appear to provide significant evidence for a narrower interpretation. A party could potentially argue that "increasing" requires a direct, one-to-one causal link between identifying a DDI and immediately prescribing the higher dose, but the specification's language about managing ongoing comorbidities in transplant patients suggests a more flexible understanding '989 Patent, col. 1:24-30

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for all six patents-in-suit. The basis for these allegations is that Annora's ANDA Product, upon approval, will be sold with a label that instructs and encourages physicians and patients to use the generic drug in a manner that directly infringes the claims of the patents-in-suit (e.g., Compl. ¶¶36-37; Compl. ¶¶45-46).
• Willful Infringement: The complaint does not use the term "willful infringement," but alleges for each patent that "Annora has had knowledge of the [patent] since at least the date of Annora's ANDA submission" (e.g., Compl. ¶38; Compl. ¶47). This allegation of pre-suit knowledge, stemming from the ANDA filing and Paragraph IV certification process, forms the basis for a potential claim of willfulness. The complaint also seeks attorneys' fees under 35 U.S.C. § 285, asserting that the case is "exceptional" (e.g., Compl. ¶40; Compl. ¶49).

VII. Analyst's Conclusion: Key Questions for the Case

• A primary issue will be one of induced infringement: Will the court find that the language in Annora's proposed product label, which will mirror the LIVTENCITY® label, constitutes active instruction and encouragement for physicians to prescribe maribavir according to the patented dosing regimens, particularly with respect to dose adjustments for drug-drug interactions (the '989 patent family) and administration under fasted conditions (the '632 patent family)?
• A second key question will be one of claim scope: For the '632 and '169 patents, can Takeda prove infringement of claims requiring "fasted conditions" based on the likely real-world use of the generic drug, or will the dispute be confined to the scope of broader claims that do not contain this limitation?
• A third question, relevant to the '940 patent, is evidentiary: Can Takeda demonstrate through discovery that Annora's manufacturing process for its maribavir tablets falls within the scope of the '940 patent's synthesis claims, or that the final product contains a chemical signature unique to that patented process?